6k
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES
EXCHANGE ACT OF 1934
Commission
File Number 1-31360
615-4211
Yonge Street
Toronto,
Ontario M2P 2A9
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form
6-K
if submitted solely to provide an attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange
on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
"Yes" is marked, indicate below the file number assigned to the registrant
in
connection with Rule 12g3-2(b): 82- ________
PreMD
Inc.
Form
6-K
On
April 10, 2006,
the Corporation
announced that a scientific abstract describing a new microwell-based
format of
LungAlert™ has been accepted for presentation at the upcoming American
Association for Clinical Chemistry Annual Meeting, July 23 - 27, 2006,
in
Chicago, Illinois. The information contained in this news release is
incorporated herein by reference and filed as Exhibit
99.1.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
PreMD
Inc.
|
| |
|
|
| |
|
|
| |
By:
|
/s/
Ronald G. Hosking
|
| |
|
Ronald
G. Hosking
|
| |
|
Vice
President and Chief Financial
Officer
|
EXHIBIT
INDEX
|
Exhibit
|
|
|
|
Number
|
|
Description
|
|
99.1
|
|
The
Registrant’s News Release
|
| |
|
|